

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6631881

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	MUHAMMAD ALI QURESHI	07/18/2019
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	LEH PHARMA LIMITED	
<b>Street Address:</b>	PARK HOUSE, 116 PARK STREET	
<b>City:</b>	LONDON	
<b>State/Country:</b>	UNITED KINGDOM	
<b>Postal Code:</b>	W1K 655	
<b>PROPERTY NUMBERS Total: 1</b>		
	<b>Property Type</b>	<b>Number</b>
	Application Number:	17188793
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Email:</b>	BostonIPDocketing@dlapiper.com	
<b>Correspondent Name:</b>	DLA PIPER LLP US ATTN: BOSTON PATENT GROUP	
<b>Address Line 1:</b>	11911 FREEDOM DRIVE	
<b>Address Line 2:</b>	SUITE 300	
<b>Address Line 4:</b>	RESTON, VIRGINIA 20910	
<b>ATTORNEY DOCKET NUMBER:</b>	425752-000151	
<b>NAME OF SUBMITTER:</b>	LISA M.W. HILLMAN	
<b>SIGNATURE:</b>	/Lisa M.W. Hillman/	
<b>DATE SIGNED:</b>	03/31/2021	
<b>Total Attachments: 4</b>		
source=425752-000151-Assign004#page1.tif		
source=425752-000151-Assign004#page2.tif		
source=425752-000151-Assign004#page3.tif		
source=425752-000151-Assign004#page4.tif		

## **INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT**

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned,

**Muhammad Ali Qureshi, Park House, 116 Park Street, London W1K6SS, UK**

(hereinafter "Assignor"), hereby sells, assigns and transfers to, the undersigned:

**LEH Pharma Limited (formerly London Eye Hospital Pharma Ltd.)  
Park House, 116 Park Street  
London W1K6SS  
UK**

and to its successors and assigns (hereinafter, "Assignee"), all of Assignor's ownership, right, title, further or other legal assignments, transfers, mortgages, legal or other charges or securities over the Assignor's interest in any intellectual property or assets of whatever nature or tenure and wherever situated, including, without limitation the United States, Canada, China, Japan, and any European Country in which patent rights are ultimately sought under European Patent Applications in Schedule 1 and forming part of the Collateral (as defined in the Security Agreement) for perfecting the security intended to be created by the Security Agreement between (1) the Assignee, (2) IOLAMD Ltd, (3) the Assignor, (4) Syneos Health UK Limited and (5) Syneos Health, LLC (f/k/a INC Research LLC) (the "Security Agreement") and for facilitating the realisation of the Collateral created or intended to be created under the Security Agreement, including the following ("Assigned IP"):

- (1) the extant patent applications and any issued patents listed on Schedule 1 (collectively, the "Patents"), and to the extent possible, exclusive right, to said Patents, and to any and all inventions described in said Patents, which may be granted therefor in the such countries, and their territorial possessions, and in and to any and all continuations-in-part, continuations, divisions, substitutes, reissues, renewals, extensions thereof, and all other applications for Letters Patent relating thereto which have been, or shall be, filed in such countries and their territorial possessions, and all rights, together with all priority rights, under any of the international conventions, unions, agreements, acts, and treaties, including all future conventions, unions, agreements, acts, and treaties;
- (2) in concepts and technologies described in such Patents ("Patented Technology") that may have been conceived by me, either solely or jointly with another to the date of this assignment;
- (3) any copyright rights related to such Patented Technology, whether registered or unregistered, together with all issuances, extensions and renewals thereof (the "Copyrights");
- (4) any trademark rights, in registrations or applications, or at common law, with all issuances, extensions, and renewals thereof, (the "Trademarks") together with the good will of the business connected with the use of, and symbolized by the Trademarks;
- (5) any and all royalties, fees, income, payments and other proceeds now or hereafter due or payable with respect to any and all of (1) - (4) above; and
- (6) any and all claims and causes of action with respect to any of (1) - (5), whether accruing before, on, or after the date hereof, including all rights to claims for damages, restitution, and injunctive and other legal and equitable relief for past, present, and fixture infringement, dilution, misappropriation, violation, misuse, breach, or default, with the right

but no obligation to sue for such legal and equitable relief and to collect, or otherwise recover, any such damages.

I authorize:


(a) Assignee to apply for and receive Letters Patent for protection of all inventions described in said Patents, in Assignee's own name, in the United States, its territorial possessions, and all foreign countries; and that, when requested to carry out in good faith the intent and purpose of this assignment, at the expense of said Assignee, but without charge to Assignee, its successors, assigns and legal representatives, the undersigned Assignor will execute (and hereby provides Assignee a Power of Attorney to execute on Assignor's behalf) all continuations-in-part, continuations, divisions, substitutes, reissues, renewals and extensions thereof, and to execute all rightful oaths, assignments, powers of attorney and other papers, testify in any legal or quasi-legal proceedings; communicate to said Assignee, its successors, and assigns all facts known to the undersigned relating to said invention and the history thereof; and generally do everything possible which said Assignee, its successors, assigns or legal representatives shall consider desirable for aiding in securing, maintaining and enforcing proper patent protection for said invention and for vesting title to said invention and all applications for patents on said invention in said Assignee, its successors, assigns and legal representatives;

(b) the U.S. Commissioner of Patents, the U.S. Commissioner for Trademarks, and the U.S. Register of Copyrights, and corresponding foreign officials or legal entities, to record and register this IP Assignment upon the request of Assignee. Following the date hereof, upon Assignor's request, and at its sole cost and expense, Assignor will take such steps and actions, and provide such cooperation and assistance to Assignee and its successors and assigns, including the execution and delivery of any affidavits, declarations, oaths, exhibits, assignments, powers of attorney or other documents, as may be necessary to effect, evidence, or perfect this assignment of the Assigned IP to Assignee, or successor thereto.

This IP assignment and any claim, controversy, dispute or cause of action (whether in contract, tort, or otherwise) based upon, arising out of, or relating to this IP Assignment and the transactions contemplated hereby shall be governed, and construed in accordance with, the laws of the United States and the State of New York, without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction).

IN TESTIMONY WHEREOF, the Assignor and an authorised signatory of the Assignee have hereunto set their signatures below.


Signature of Assignor:



Name: Muhammad Ali Qureshi

Date: 18.07.2019

Signature of Assignee:



for and on behalf of LEH Pharma Ltd

By: M. A. Qureshi

Date: 18.07.2019

**SCHEDULE 1**

<b>Juris- diction</b>	<b>Application No.</b>	<b>Filing Date</b>	<b>Earliest Possible Priority Date</b>	<b>Title</b>	<b>Inventors</b>
US	16/057,210	2018-08-07	GB20130014428 2013-08-12  GB20140005005 2014-03-20  GB20140013158 2014-07-24	Intraocular lens system	Qureshi, M Artal, Pablo Scott, Robbie Tabernero, Juan
US	Provisional no. 62/770,999	2018-11-23	N/A	Initial clinical results with a novel monofocal-type intraocular lens for extended macular vision in patients with macular degeneration	Qureshi, M Artal, Pablo Scott, Robbie Tabernero, Juan
CA	20142921118	2014-08-12	GB20130014428 2013-08-12  GB20140005005 2014-03-20	Intraocular lens system	Qureshi, M Artal, Pablo Scott, Robbie Tabernero, Juan
CA	20142921120	2014-08-12	GB20130014428 2013-08-12  GB20140005005 2014-03-20  GB20140013158 2014-07-24	Intraocular lens system	Qureshi, M Artal, Pablo Scott, Robbie Tabernero, Juan
CN	CN20148053786	2014-08-12	PCT/GB2014/05245 9  GB20130014428 2013-08-12  GB20140005005 2014-03-20  GB20140013158 2014-07-24	Intraocular lens system	Qureshi, M Artal, Pablo Scott, Robbie Tabernero, Juan
CN	CN20148054242	2014-08-12	PCT/GB2014/05245 8  GB20130014428 2013-08-12  GB20140005005 2014-03-20	Intraocular lens system	Qureshi, M Artal, Pablo Scott, Robbie Tabernero, Juan

EP	EP20140753118	2014-08-12	GB20130014428 2013-08-12  GB20140005005 2014-03-20	Intraocular lens system	Qureshi, M Artal, Pablo Scott, Robbie Tabernero, Juan
EP	EP20140753119	2014-08-12	GB20130014428 2013-08-12  GB20140005005 2014-03-20  GB20140013158 2014-07-24	Intraocular lens system	Qureshi, M Artal, Pablo Scott, Robbie Tabernero, Juan
GB	GB20140005005	2014-03-20	GB20130014428 2013-08-12	Intraocular lens system	Qureshi, M Artal, Pablo Scott, Robbie Tabernero, Juan
GB	GB20140013158	2014-07-24	GB1314428.2 2013-08-12  GB1405005.8 2014-03-20	Intraocular lens system	Qureshi, M Artal, Pablo Scott, Robbie Tabernero, Juan
JP	JP20160533953	2014-08-12	GB20130014428 2013-08-12  GB20140005005 2014-03-20  GB20140013158 2014-07-24  WO2014GB52459 2014-08-12	Intraocular lens system	Qureshi, M Artal, Pablo Scott, Robbie Tabernero, Juan
JP	JP20160533952	2014-08-12	GB20130014428 2013-08-12  GB20140005005 2014-03-20  WO2014GB52458 2014-08-12	Intraocular lens system	Qureshi, M Artal, Pablo Scott, Robbie Tabernero, Juan